ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sacituzumab tirumotecan

Also written as “Sacituzumab tirumotecan”, “SKB264” and “Sacituzumab Tirumotecan”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Breast Neoplasms · Ovarian Neoplasms · Endometrial Neoplasms, led by 4 companies.

Drug pageSacituzumab tirumotecan: every studyAll 113 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 3, 202350 company-led studies, 48 open or runningLicense: Kelun-Biotech → MerckNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only2928 open or runningphase 3since Oct 3, 2023Apr 1, 2022May 10, 2027phase 3 · NCT06074588
Sichuan Kelun Pharmaceutical1716 open or runningphase 3since Apr 15, 2022Apr 15, 2022Nov 2026phase 3 · NCT06448312
Klus Pharmaits history only33 open or runningphase 2since Oct 29, 2019Oct 29, 2019Nov 30, 2027phase 2 · NCT05642780
Convalife (Shanghai)its history only11 open or runningphase 2since Aug 22, 2025Aug 22, 2025Aug 12, 2028phase 2 · NCT07157956
  • Named in Merck’s own pipeline as sacituzumab tirumotecan (MK-2870), phase 4, as of Nov 2, 2026 (source).

Also a collaborator on its studies: Daiichi Sankyo and Myriad Genetics.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How Klus Pharma and Convalife (Shanghai) relate to it is not in the registry or these sources.

History and studies of Sichuan Kelun Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Apr 15, 2022.

  1. Jun 30, 2022Phase 2 study in Triple Negative Breast NeoplasmsNCT05445908 · 184 enrolled · China
  2. Nov 10, 2022Phase 2 study in Selected Subjects With Advanced Solid TumorsNCT05631262 · 321 enrolled · China
  3. Apr 18, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05870319 · 376 enrolled · China
  4. Aug 6, 2023Named sacituzumab tirumotecanINNProposed as its International Nonproprietary Name in WHO's List 129 · before, SKB264
  5. Oct 7, 2023Phase 3 study in Breast NeoplasmsNCT06081959 · 376 planned · China
  6. Feb 19, 2024Phase 3 study in Triple Negative Breast NeoplasmsNCT06279364 · 537 enrolled · China
  7. Jun 3, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06448312 · 406 enrolled · China
  8. Oct 31, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06670196 · 420 enrolled · China
  9. Nov 22, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06711900 · 432 enrolled · China
  10. Jun 19, 2025Phase 3 study in Breast NeoplasmsNCT07071337 · 430 planned · China
  11. Dec 11, 20253 phase 2 studiesNCT07329322, NCT07324629, NCT07341100
  12. May 7, 2026Phase 2 study in Advanced Solid TumorsNCT07586943 · 530 planned · China
  13. Jul 3, 2026Phase 2 study in NSCLCNCT07697586 · 206 planned · China
  14. Sep 28, 2026Phase 2 study in Non-Squamous Non-Small Cell Lung CancerNCT07854509 · 110 planned
  15. Oct 21, 2026Primary completion moved from 2026-07 to 2027-04Date moved laterphase 3 · +9 months · NCT06279364

Ahead

  1. Nov 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06448312
  2. Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06711900
  3. Dec 30, 2026Primary completion: phase 2 study in Selected Subjects With Advanced Solid TumorsNCT05631262
  4. Dec 31, 2026Primary completion: phase 3 study in Breast NeoplasmsNCT06081959

TargetBeta

“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugate…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) ”NCIt, by rule

Other programs on TACSTD2

ProgramCompanyFurthest phaseStudies
sacituzumab govitecanruleGilead Sciencesphase 430
datopotamab deruxtecanruleAstraZenecaphase 329
JSKN016ruleAlphamab Oncologyphase 35
Anti-TROP2 Antibody-drug Conjugate ESG401ruleQilu Pharmaceuticalphase 33
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036CruleMinghui Pharmaceuticalphase 23
sacituzumab drozuntecanruledualitybio-incphase 22
Anti-TROP-2 Antibody-drug Conjugate OBI-902ruleobi-pharma-incphase 21
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharmaphase 21
JSKN016HCruleAlphamab Oncologyphase 11
KH815ruleChengdu Kanghong Pharmaceutical Groupphase 11

Studies

All 17 Sichuan Kelun Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07854509Non-Squamous Non-Small Cell Lung Cancer2Not yet recruitingDec 30, 2027110
NCT07697586NSCLC · China2RecruitingAug 2028206
NCT07586943Advanced Solid Tumors · China2RecruitingDec 2029530
NCT07341100Carcinoma, Ovarian Epithelial · China2Active, not recruitingJan 202820
NCT07329322Carcinoma, Non-Small-Cell Lung · China2RecruitingAug 31, 202730
NCT07324629Thymoma · China2RecruitingApr 202830
NCT07071337Breast Neoplasms · China3RecruitingJul 2027430
NCT06711900Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingDec 2026432
NCT06670196Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingMay 2027420
NCT06448312Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingNov 2026406
NCT06279364Triple Negative Breast Neoplasms · China3Active, not recruitingApr 2027537
NCT06081959Breast Neoplasms · China3RecruitingDec 31, 2026376
NCT05870319Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingJul 11, 2024376
NCT05631262Selected Subjects With Advanced Solid Tumors · China2Active, not recruitingDec 30, 2026321
NCT05445908Triple Negative Breast Neoplasms · China2CompletedJul 31, 2026184
NCT05351788Carcinoma, Non-Small-Cell Lung · China2RecruitingAug 2026110
NCT05347134Triple Negative Breast Neoplasms · China3Active, not recruitingNov 30, 2023254

How it is read

Names in the registry

  • “Sacituzumab tirumotecan”, 22 entries
  • “SKB264”, 15 entries
  • “Sacituzumab Tirumotecan”, 5 entries
  • “SKB264+SKB118”, 2 entries
  • “sac-TMT”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.